Nortech Systems Inc. (NSYS) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Nortech Systems Inc. is a global Electronics Manufacturing Services (EMS) provider operating in the Medical Device, Medical Imaging, Aerospace and Defense, and Industrial markets. The company is currently undergoing a restructuring plan involving the closure of its Blue Earth, Minnesota facility and the consolidation of production into its Bemidji facility.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Net Sales | $26,895 | $34,215 | (21.4%) |
| Gross Profit | $3,078 | $5,448 | (43.5%) |
| Gross Margin | 11.4% | 15.9% | -450 bps |
| Operating Loss | $(1,613) | $1,155 | N/A |
| Net Loss | $(1,316) | $765 | N/A |
| Diluted EPS | $(0.48) | $0.26 | N/A |
| Cash from Operations | $(2,930) | $2,828 | N/A |
| Line of Credit Borrowed | $11,955 | $8,695 | +37.5% |
| Cash & Equivalents | $1,162 | $4,028 | (71.2%) |
Note: All figures in thousands except per share data and percentages.
Material Changes vs. Prior Period
- Revenue Decline: Net sales dropped 21.4% year-over-year. The Aerospace and Defense segment saw the steepest decline at 43.8%, attributed to delays in customer approvals for products transferred from the closed Blue Earth facility to Bemidji. Medical Device sales fell 24.8% due to customer inventory re-balancing and lower productivity during facility consolidation.
- Margin Compression: Gross margin contracted by 450 basis points to 11.4%, driven by reduced facility utilization, manufacturing inefficiencies during the plant transition, and lower sales volume.
- Restructuring Charges: The company recorded $266 in restructuring charges, primarily for workforce reductions ($235) and facility closure costs ($31) related to the Blue Earth site.
- Operating Cash Flow: Operating cash flow turned negative at $(2,930), compared to positive $2,828 in the prior year, largely due to increased accounts receivable balances and higher inventory reserves.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management expects the production transfer issues and customer approval delays to be resolved over the next two quarters. The company has implemented cost-cutting initiatives and plans to actively reduce inventory levels to drive reduced borrowings in the remainder of 2025. The 90-day shipment backlog increased slightly to $26,742, while total order backlog decreased 20.5% year-over-year to $68,332 due to shorter customer lead times and inventory rebalancing.
Financing and Liquidity Risks: The company is not in compliance with its leverage and fixed charge coverage ratios under its $15 million Bank of America Revolver.
- Amendments: On March 27, 2025, and May 14, 2025, the company secured amendments (First and Second Amendments) waiving non-compliance and deferring ratio compliance until Q4 2025.
- New Covenants: The Second Amendment requires maintaining adjusted EBITDA of at least $1,000 in Q2 2025, $1,300 in Q3 2025, and $1,600 in Q4 2025. It also mandates a minimum "Liquidity" (cash + revolver availability) of $2,500.
- Cost of Capital: Borrowing rates were increased by 1% under the First Amendment and an additional 25 basis points under the Second Amendment. The weighted-average interest rate was 7.2% as of March 31, 2025.
Key Risks:
- Continued delays in Aerospace and Defense customer approvals.
- Customer inventory rebalancing reducing order visibility.
- Failure to meet the new EBITDA and liquidity covenants in subsequent quarters.
Investor Verification Checklist
- Covenant Compliance: Verify if the company meets the new EBITDA targets ($1,000 for Q2 2025) and the $2,500 liquidity floor in upcoming filings.
- Production Transition: Monitor the status of Aerospace and Defense customer approvals for the Bemidji facility to assess revenue recovery potential.
- Inventory Levels: Track inventory reduction progress to confirm management's plan to improve operating cash flow.
- Customer Concentration: Note that Customer A represents 31% of Q1 2025 net sales and 22% of accounts receivable.
- Debt Utilization: Review the line of credit utilization, which stands at $11,955 of $15,000 available, with only $3,045 in unused availability subject to liquidity caps.